Table 3.

Endocrine IRAEs with PD1 and PDL1 antibodies

PD1 antibodies
Study	Antibody	Cohort		Endocrinopathy
		Age (range)	n	Hypothyroidism	Hyperthyroidism	Adrenal insufficency	Hypophysitis	Other thyroid#	T1DM
Topalian, et al(2012)12	Nivolumab	63 (29–85)	296	7ǂ	3	NR	2§	NR	NR
Topalian, et al(2014)11	Nivolumab	61 (29–85)	107	6ǂ	2	NR	1	1	NR
Motzer, et al(2015)109||	Nivolumab	61 (SD 9)	168	10ǂ	NR	NR	NR	NR	NR
Gettinger, et al(2015)67##	Nivolumab	65 (38–85)	129	NR	NR	NR	NR	NR	NR
Rizvi, et al(2015)113	Nivolumab	65 (57–71)	117	3ǂ	NR	1ǂ	NR	1	NR
Brahmer, et al(2015)114	Nivolumab	62 (39–85)	135	5ǂ	NR	NR	NR	NR	NR
Robert, et al(2015)107	Nivolumab	64 (18–86)	210	9ǂ	7ǂ	NR	1	NR	1
Larkin, et al(2015)132	Nivolumab	59 (25–90)	316	27ǂ	13ǂ	NR	2	NR	NR
Robert, et al(2014)66	Pembrolizumab	59 (18–88)	173	7ǂ	3ǂ	NR	2	NR	NR
Robert, et al(2015)115	Pembrolizumab	61–63 (18–89)	556	52ǂ	27ǂ	NR	3	NR	2
Garon, et al(2015)116	Pembrolizumab	64 (28–93)	495	34ǂ	9ǂ	NR	NR	NR	NR
Total			2702	160 (5.9%)	71 (3.3%)	2 (1.7%)	10 (0.6%)	1 (1.3%)	2 (0.4%)
Event/Totalǂǂ				160/2573	71/2153	2/117	10/1658	3/224	3/766
PDL1 antibodies
Study	Antibody	Cohort		Endocrinopathy
		Age (range)	n	Hypothyroidism	Hyperthyroidism	Adrenal insufficency	Hypophysitis	Other thyroid#	T1DM
Brahmer, et al(2012)	MDX-1105	63 (29–83)	207	6ǂ	NR	2ǂ	NR	2	NR
McDermott, et al(2016)	Atezolizumab	61 (33–81)	70	6ǂ	NR	NR	NR	NR	NR
Total			277	12 (4.3%)	NA	2 (1.0%)	NA	2 (1.0%)	NA
Event/Totalǂǂ				12/277	NA	2/207	NA	2/207	NA

^#Includes autoimmune thyroiditis, unspecified thyroid disorders.

^ǂUnspecified cause.

^§Reported as <1% of 296 patients, but exact number of event not reported;

^||18 endocrinopathies reported by no specifics given other than 10 hypothyroidism.

^##Eight endocrinopathies reported but no specifics given.

^ǂǂPercentage determined by total number of events divided from total number of patients only from studies reporting event. IRAE, immune-related adverse event; NA, not applicable; NR, none reported; T1DM, type 1 diabetes mellitus